AI Terminal
ECO ANIMAL HEALTH GROUP PLC
Share Issue/Capital Change • Aug 13, 2025
7612_rns_2025-08-13_a3a40c97-48f5-4562-9e55-f54db81f276c.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0731V
Eco Animal Health Group PLC
13 August 2025
13 August 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Block Listing Return
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | ECO Animal Health Group plc | |||
| Name of scheme: | Executive Share Option Scheme and Unapproved Share Option Scheme | |||
| Number and class of securities originally listed and the date of admission: | 1,500,000 ordinary shares of 5 pence each on 20 July 2017 | |||
| Period of return: | From: | 9 February 2025 | To: | 12 August 2025 |
| Balance of unallotted securities under scheme(s) from previous return: | 375,505 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 0 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 375,505 | |||
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) |
020 8447 8899 |
| Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher |
020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Lydia Zychowska |
020 7597 5970 |
| Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
| ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700 [email protected] |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRUUSRRVOUWAUR